<SEC-DOCUMENT>0001193125-14-114475.txt : 20140325
<SEC-HEADER>0001193125-14-114475.hdr.sgml : 20140325
<ACCEPTANCE-DATETIME>20140325162809
ACCESSION NUMBER:		0001193125-14-114475
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140324
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140325
DATE AS OF CHANGE:		20140325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		14716285

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d700273d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;24, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CERUS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21937</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>68-0262011</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File No.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2550 Stanwell Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Concord, California 94520 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (925)&nbsp;288-6000 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On March&nbsp;24, 2014, the Board of Directors (the &#147;Board&#148;) of Cerus Corporation (the &#147;Company&#148;), at the
recommendation of the Nominating and Corporate Governance Committee of the Board, elected Frank Witney, Ph.D., to the Board effective immediately. Dr.&nbsp;Witney will serve in the class of directors whose term of office expires at the
Company&#146;s 2015 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Also effective March&nbsp;24, 2014, Dr.&nbsp;Witney was appointed to serve on the
Compensation Committee of the Board (the &#147;Compensation Committee&#148;). Dr.&nbsp;Witney has served as the President and Chief Executive Officer, and as a member of the Board of Directors, of Affymetrix, Inc, since July 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s Non-Employee Director Compensation Policy, adopted by the Board on February&nbsp;14, 2014 (the &#147;Director
Policy&#148;), as a non-employee member of the Board, Dr.&nbsp;Witney is entitled to receive an annual cash retainer in the amount of $40,000 for service as a Board member and will be reimbursed for reasonable expenses incurred in attending meetings
of the Board. Also under the Director Policy, Dr.&nbsp;Witney is entitled to an additional annual cash retainer of $8,000 for his service on the Compensation Committee. Both annual amounts will be paid in quarterly installments, with the amount for
the first quarter paid on a prorated basis for the portion of the quarter for which he served on the Board and Compensation Committee. As a non-employee director, Dr.&nbsp;Witney is not entitled to perquisites or retirement benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his election, Dr.&nbsp;Witney received an initial stock option grant under the Company&#146;s 2008 Equity Incentive Plan,
as amended (the &#147;2008 Plan&#148;), to purchase 45,000 shares of the Company&#146;s common stock pursuant to the Director Policy on March&nbsp;24, 2014 (the &#147;Initial Option&#148;). The Initial Option vests in equal monthly installments over
a four-year period. Dr.&nbsp;Witney will also automatically receive pursuant to the Director Policy an option to purchase 30,000 shares of common stock under the 2008 Plan on the first trading day following each annual meeting of the stockholders of
the Company if he is serving as a non-employee director as of such date (the &#147;Annual Option&#148;). The Annual Option will vest in twelve equal monthly installments beginning one month from the date of grant, with full vesting to occur on the
earlier of one year from the grant date, or the trading day immediately prior to date of the next annual meeting. Annual option grants under the Director Policy are non-discretionary. All options granted pursuant to the Director Policy have a term
of ten years, have an exercise price equal to 100% of the fair market value of the Common Stock on the date of grant and are subject to the terms of the 2008 Plan. In the event&nbsp;of a &#147;change in control&#148; of the Company, as defined by
the 2008 Plan, all outstanding options held by Dr.&nbsp;Witney will become fully vested immediately prior to such change in control event, subject to Dr.&nbsp;Witney&#146;s &#147;continuous service&#148;, as defined by the 2008 Plan, to the Company
at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Dr.&nbsp;Witney&#146;s election to the Board, he and the Company entered into the Company&#146;s
standard indemnity agreement for the Company&#146;s directors and officers, which requires the Company to indemnify Dr.&nbsp;Witney, under the circumstances and to the extent provided for therein, against certain expenses and other amounts incurred
by Dr.&nbsp;Witney as a result of being made a party to certain actions, suits, proceedings and the like by reason of his position as a director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing the appointment of Dr.&nbsp;Witney to the Board is attached as Exhibit 99.1 to this current report and
is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Press Release, dated March&nbsp;25, 2014, entitled &#147;Frank Witney Joins Cerus Board of Directors.&#148;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>CERUS CORPORATION</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March 25, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ Kevin D. Green</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Kevin D. Green</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March 25, 2014, entitled &#147;Frank Witney Joins Cerus Board of Directors.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d700273dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g700273g98e31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Frank Witney Joins Cerus Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONCORD, Calif.&#151;(BUSINESS WIRE) &#151; March&nbsp;25, 2014 &#151; Cerus Corporation (NASDAQ: CERS) announced&nbsp;today that Dr.&nbsp;Frank Witney,
president and chief executive officer of Affymetrix, has joined its board of directors and the compensation committee. Dr.&nbsp;Witney joins the board with over 30 years of experience in the life science industry, specifically focused on corporate
strategy and commercialization of products in the life science tools and diagnostics space. Dr.&nbsp;Witney will be filling the board seat recently left vacant by B.J. Cassin upon his retirement from the board on December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On behalf of the management team and board of directors, I am delighted to welcome Dr.&nbsp;Witney to Cerus,&#148; said Obi Greenman, president and
chief executive officer of Cerus Corporation.&nbsp;&#147;His extensive commercial experience in the life science space will serve as a valuable asset to the Company as we prepare for a possible launch of our INTERCEPT platelet and plasma products in
the U.S.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to his current position at Affymetrix, Dr.&nbsp;Witney served as president and chief executive officer of Dionex Corp. from April
2009 through its $2.1 billion sale to Thermo Fisher Scientific Inc. in May 2011. Dr.&nbsp;Witney served as the executive vice president and chief commercial officer of Affymetrix until April 2009, following Affymetrix&#146;s acquisition of Panomics,
Inc., where he had been president and chief executive officer since July 2002. Dr.&nbsp;Witney was a post-doctoral fellow at the National Institutes of Health and holds a Ph.D. in Molecular and Cellular Biology and an M.S. in Microbiology from
Indiana University, and a B.S. in Microbiology from the University of Illinois. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT CERUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and
platelets. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INTERCEPT and the INTERCEPT
Blood System are trademarks of Cerus Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements. Any statements contained in this press
release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to a potential commercial launch of the INTERCEPT Blood System for platelets and plasma in the
U.S.. These forward-looking statements are based upon the company&#146;s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks
associated with the uncertain and time-consuming and regulatory process, including the risk that Cerus may encounter unanticipated difficulties complying with the prescribed submission timing or other modular PMA requirements related to the
INTERCEPT Blood System for plasma or for platelets or that Cerus&#145; PMA submissions might not be approved by the FDA in a timely </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g700273g98e31.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
manner or at all, risks associated with the commercialization and market acceptance of the INTERCEPT Blood System, as well as other risks detailed in the Cerus&#146; filings with, the Securities
and Exchange Commission (SEC), including in Cerus&#146; annual report on Form 10-K for the quarter ended December&nbsp;31, 2013, filed with the SEC on March&nbsp;7, 2014. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lainie Corten </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sr Director, Global Marketing&nbsp;&amp; Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(925)&nbsp;288-6319 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g700273g98e31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g700273g98e31.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``W`)H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**R?'7C
MS1?A?X.U+Q%XDU;3]"T'1[=KJ^U"_N%M[:TB499W=B%51ZDU\+Z?_P`%E?'/
M[66N7UG^RK^S_P")?BMH5G*]M)XU\07Z>&_#QD4D$P-,I>X`/51L<?W<8)`/
MOZBOA/6/B_\`\%$-*L_M\/P@_9SU*/=O_LNV\2WJWH3D[/,D*P[N`N[.,G.,
M9QY)H_\`P<(_$/X/?M'^$OA/\>/V8_$7PZ\4>+=4M-*L[RWUQ;BSN6GGC@\Z
M+,(22)6?EHII!VSF@?*?J/17A?[0G[;=K^S[\28_#]UX>N-1C>SCN_M,5V$8
M;F<;=A3MMZ[N<]JX_P#X>D:#_P!"KK'_`($1U\3C?$;AS!XB>$Q.*49P=I)Q
MGHU_V[9_+0^MPG`>?8JA#$X?#N4)JZ:<=4_^WOS/J2BOEO\`X>D:#_T*NL?^
M!$==#\&?V^K/XT?%K2?"]GX:NK-=4\W_`$J:\4F+RX7E^X$YSLQ]X=<^U9X7
MQ*X:Q%>&&H8I2G.2C%*,]7)V2^'2[>[T[E8C@#/Z%&=>MAFHP3DW>.B2NW\7
M;HM3Z#HKY5^,'[:OQ\\)?&[Q%X8\%_LF^)O'F@Z+*B6OB+_A--,T>UU13'&Y
M:-+K:>&<IC)R4)]<>,ZK_P`'"GA_]G[XPZ?X)_:*^#7Q*^`^H:H";?4+Y8M6
MTME#8,@G@P9(QE06A23:3@XQFONCY"S/T0HK%_X2Y?$GP\;7?";:9XD%]IYO
MM'*7P2SU/='OAQ<(L@6.3*_O%5\*VX!NA_.G]I__`(.#_$7[(G[4-O\`!WQ=
M^SOJC>.=4:S728=.\807%KJGVJ3RX2DK6Z;0SY7YE!#*00.M`)7/TPHKG?A9
MKGB;Q'X+M[SQ=X?T_P`+ZW*S>;IUEJIU2.!0<+F;R8LL1R0%P,]36MK]Q?6F
M@WTNFVMO?:E';R/:6T]P;>*XE"DHCR!7,:LV`6",5!SM;&""+E%?GM\6/^"U
M_C[X,_MK^'_V?]8_9QO9?B)XM6WGT1;3QI!+I^H6\OF@W`F-LI6-#!*&W("/
M*?@8&?J/]H_]MWPC^Q-^S='\0_C/>6'@U%1(Y-/M+IM2EN+M@2+6U(2-KAS@
M\[%``9FVJI8`['LU%?"O@/\`X*(?M/\`[3_A6/Q+\*_V58M+\(ZC$9M)U/Q[
MXRATJZU&-L&.7[#'$\D:E3NR7(8'Y6P,GS_XY_\`!9O]HC]B_P`1:/#\8_V2
M)[#0?$%_!IEEKOA_QFFH6?GROL5&*6[[6<_=20QL=IP&[`<I^E5%%%`C\>?^
M"LGQ3U3_`(*=_P#!6/X<_L6:)JEUI_P^T.YBU?QY+9R[3?2);F\>%F':*W"J
MF21Y]Q\RYB4C];/AW\.]#^$G@72?#/AG2K+0_#^@VJ66GV%I&(X;6%!A451V
M`_$]3DU^(/\`P23U5_$7_!SQ^T5<:C(MS<P:AXP@MWE`W((M62%`ONL*[>.=
MH/O7[L4%2[!7A?[>'[*L?[3_`(7^'<UOIMG>Z]\/?B+X:\6Z?),51K>*UU6V
M:](8_P#3E]I.T??95&"<5[I102<OXJ^"?A'QUKZZIK7AW2M5OUC6$2W<`F(1
M22!ALCJ3V[U!_P`,^^`?^A'\(?\`@FM__B*\3_:Q_:^\7_`[XR1Z'H-GI%]:
MR:=%<^7=6TDC[V:0$@HZGHHKD(?^"@OQ+GB5U\#6,BL,AELKHAOI\U?E.8<=
M<*8;'5L+B:/[V$FI/V7-=]7=)W]6?I6!X-XDQ&#I8BA5_=RBG%>UM9=%9M6^
M1]-_\,^^`?\`H1_"'_@FM_\`XBGZ%\!_!GA?Q+;ZQI?AC1=-U*T+F&>TM5A:
M/<I1L!0!RI(Z=S7S&W_!0+XF(I9O`MF%'))LKKC_`,>K8_9X_;:\:_%OX]:#
MX;UC3]%T^PU#[0TJP6LL<K!+>61>7D;^)!T'8UEA>/>$JV+HX>C1_>3G&,?W
M-K2<DHN[2M9M:K5%XG@OB:EAJM>K5]R,9.7[V]XI-M63=[KIU/K"OB7_`(.$
MOV;M&_:%_P""67Q(N;^QAGUCP':#Q/H]V0/-LI;=E:8J3CA[?SD([A@<$A:^
MIOCG^T9X%_9E\*6^O?$'Q5H_@_1+FY6SCU#5)Q;VIF9698S(WRJQ",0"1G:<
M5^?7_!5O]OW0_P!O;]GS4_V=_P!F*ZC^,7Q!^),EO8ZE<Z"C7&E>&M-\U9);
MBZO-OD1A]GEC+<!G)PP0-^MGYI'<Z7_@UU^(6N>._P#@E-I-OK-Q-<P^&_$6
MHZ3I;2[BRV@,<RH">JK)-*HQP``H^[7QW_P73\)1ZE_P<6?LQVL+F&378_"(
MDD;Y@KMXBNX0<>@55X]C7ZQ_\$U_V*[/_@GU^QAX+^%MO=Q:E>:';O-JE]&I
M5+V^F=I9Y%SSL#N53(!V(F><U^6G_!;?_E9)_9%_[DW_`-2B\H&MS]P****"
M#\D_V\O^5J3]ES_L1T_]&:_7C?\`P=I>(=:\*?M1_L]ZEJUBVJ>`M.M+B[CL
M7)\F\NH[N%KN-L@IEH1;+T)PQR,5[)^WE_RM2?LN?]B.G_HS7Z^_/^"@G[`/
M@3_@H]^SW>>`/'-O-''YGVS2M4M<"[T:\565)XB>#PQ5D;Y75B#@X8!I>UCL
M?V8_VFO`_P"U[\&-'\=_#W7+/7O#>K1`QR0,/,M9-H+03)UBF3(#1M@J?8@F
M]\>_@7X?_:1^%U]X0\3PRSZ/?3VMRXB8+(DMM<Q7,+J2"`5EA1LX[5_.#\2?
M@!^UI_P;E?'1_$WAW4;F;P;?3B%=;L8GNO#?B"//R0WL!XAFP2`K[7!W^5(P
M!>OU]_X)'_\`!=_X?_\`!3""'PKJEO%X%^+5O`TLNA2S&2VU94&7ELI2!OP/
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MXJ\6Z7X%T&?5-:U&RTG3;4J)KJ[F6&&+<P1=S,0!EF51GJ2!7Y_>&O\`@Z'_
M`&4=8TEIM3UCQQX9OH\B33=3\-3&ZB<9RC>098PP(Q]_K7EWC?\`X*L:C_P5
MX^/_`,+?A+\$/ASX^D^%[^,M+UKQQXNU32F@M9=/T^[CO3;H4++''(T"`O(Z
M,S!8PGS<@<K/U@$:J[,%7<V`3CDXZ4ZOF/\`:M?XP+\:8O\`A`?^$@_LK[!#
MN^SA3;>;ODS]_P"3.-N?;&:XC_C*+_J+_P#DC7YOF'B)]4Q=3"_V?B*G))KF
MA3YHNW5.Z/NL%P+]9PU/$_7J$.=)\LYVDO)JS/M.FM&KLI958H<J2/NG&./P
M)_.OB[_C*+_J+_\`DC72?L^O\<#\?]!_X37_`(2+^PLW'VK>$^R_\>TFS=Y?
MR_?V8S_%CO487Q(^L8FEAO[.Q,.>48\TJ=HKF:5V[O17NS3$\!^QH5*_UZA+
MDC*5HU+R=E>R5EJ]D>]_M%?L^^%?VJ?@EXD^'OC;38]6\,^*;-K.]@;A@#@K
M(C?PR1N%=''*NBD<BOPS_9<^,_CC_@V?_P""@>K?"KXF->ZS\"/B%<+>6^K1
M1%HS%D1QZI"B@GSHUQ'<P+\Q`4C<%A+_`-`%>%_\%"?^"?O@7_@I!^SS?>`?
M&T$D)W&[TC5K=1]KT2\"E4GCSPPP2&0_*ZDC@X8?I9\#%]&>R>%/%>F^._"^
MFZWHM]:ZIH^L6T=[97EK()(;N"10Z2(PX964@@CJ#7X9_P#!RY-)\%?^"N_[
M.'Q0U`21Z%8:9I;>8,K\VG:U-=3889Y"7,1X'&1UKIOV+/C#^TE_P0(^)O\`
MPJ;XQ>!_%?Q*^`=]=.VD>(O#5G+J<>B[B29;?:,K&QRTEI+L93N>/=SYOU!_
MP4#^&'P1_P""_/[-<'A/X>?$+1_^%C^'M^M^%Y[NVN+2:V8JJS0W$$L:S+#*
MNU6(7<C)&V&V%&!K1GZ*03QW4"2Q.LD<BAD=3N5@>00>X-.K\G/V)/\`@I]\
M9/\`@G-\,]-^$O[5WP4^*0@\'VXT[1O&_A[2&UBSO;2%=J)<21L48HB@"2-V
M9EV[T5@SM[=XQ_X+=M\6M*;2?V<O@G\6_BWXPU!`MC<7GAV?1O#UFS#"RW5W
M<;-J!CTPH;:PWKPU`N5GC'Q0AC_:!_X.PO`$>GK'=1?!OX>,VKA%W>0S6]\\
M98@_*0^K6IR?51CG-?J;I?BG3=;U74K"SU"RNK[194@U"WAF5Y;*1XUE1)5!
MRC-&Z.`V,JP/0U\C?\$G_P#@F[X@_9$D\=?$SXJZ]:^+OCI\8+P:CXFU&W&;
M;38\ETL;<G^!68[BH52%B55VQ*3\X?'?]K_XU_\`!,O_`(*R_&GQ9J'P4^(7
MQ"^`?Q0.B7`U+P_IS7CV$UKI-K;/-$R@H"721&BF:/=Y:LK``E@-]C]1_%OA
M'2O'OAF^T77--L-8T?5(6MKRQO8%N+>ZB889)(V!5E(X(((-?S?_`/!>?_@F
M[9?\$E?VI_`?Q(^#NH7OA[P_XKNI=2TBW2<O-X;U.SDBD98F;),)$L3(&+$%
M9%)("Y_6[2/^#@7X'^(=)F?3O#WQHU#68"$?0[;P#?2Z@DA!Q&0%\H,2"`#)
MC(ZXYKYS^+W[&_QD_P""\O[5W@GQ-\4O`&M?!+]G7X<2O+8:'X@/D^)/$AE:
M-IO-MU.ZW,BQ1(2^/*7=L,C%B`(Z;GZ@?`'Q]=?%7X$>"?%%];_9+WQ)H-CJ
MMQ!MV^3)/;QRLF.V"Q&/:NNJ.SLX=.M(K>WBC@MX$$<<<:A4C4#`4`<``<`"
MI*"0HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
